Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear.[1][2][3] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.[2][4][5][6]
History
editPembrolizumab was approved by the US Food and Drug Administration in May 2017.[7]
Larotrectinib was approved by the FDA in November, 2018.[7]
Selpercatinib (LOXO-292) received priority review in September 2018[7] and was approved for medical use in the United States in May 2020.[8][9]
Entrectinib was approved for medical use in the United States in August 2019,[10][11] in Australia in May 2020,[12] and in the European Union in July 2020.[13]
Pralsetinib was approved for medical use in the United States in September 2020.[14][15]
Dabrafenib and trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. [16]
Tissue-agnostic cancer drugs that are under development as of May 2022[update] include Selitrectinib (Loxo-195) and anti-ERBB3 antibodies.[7]
References
edit- ^ Bacon, John (28 November 2018). "FDA approves new drug reflecting cutting-edge, 'tissue-agnostic' effort to beat cancer". USA Today. Retrieved 3 December 2018.
- ^ a b Garber, Ken (16 June 2017). "In a major shift, cancer drugs go 'tissue-agnostic'". Science. 356 (6343): 1111–1112. doi:10.1126/science.356.6343.1111. PMID 28619894.
- ^ Garber, Ken (16 June 2017). "Tissue-agnostic cancer drug pipeline grows, despite doubts". Nature. 17 (4): 227–229. doi:10.1038/nrd.2018.6. PMID 29520093. S2CID 4417987.
- ^ Photopoulos, Julianna (2020). "The future of tissue-agnostic drugs". Nature. 585 (7826): S16–S18. Bibcode:2020Natur.585S..16P. doi:10.1038/d41586-020-02679-6. S2CID 221884179.
- ^ Adashek, Jacob J.; Subbiah, Vivek; Kurzrock, Razelle (2021). "From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm". Trends in Cancer. 7 (1): 15–28. doi:10.1016/j.trecan.2020.08.009. PMID 33008795. S2CID 222161382.
- ^ Dun, Lauren (27 Nov 2018). "FDA approves a new cancer drug targeted to genetic mutation, not cancer type". NBC. Retrieved 17 Dec 2018.
- ^ a b c d Wang, Brian (June 19, 2019). "New Gene Targeting Cancer Drugs And Other Advances in Cancer Medicine – NextBigFuture.com". www.nextbigfuture.com. Retrieved 2019-06-19.
- ^ "FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion". U.S. Food and Drug Administration (FDA) (Press release). 8 May 2020. Retrieved 2022-05-04.
- ^ "Retevmo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 2022-05-04.
- ^ "FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor". U.S. Food and Drug Administration (FDA) (Press release). 15 August 2019. Archived from the original on 14 September 2019. Retrieved 23 November 2019.
This article incorporates text from this source, which is in the public domain.
- ^ "Drug Approval Package: Rozlytrek". U.S. Food and Drug Administration (FDA). 16 September 2019. Retrieved 23 November 2019.
- ^ "Rozlytrek Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 25 May 2020. Retrieved 16 August 2020.
- ^ "Rozlytrek EPAR". European Medicines Agency (EMA). 26 May 2020. Retrieved 11 September 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "FDA approves pralsetinib for lung cancer with RET gene fusions". U.S. Food and Drug Administration (FDA). 4 September 2020. Retrieved 2022-05-04.
- ^ Markham A (November 2020). "Pralsetinib: First Approval". Drugs. 80 (17): 1865–1870. doi:10.1007/s40265-020-01427-4. PMID 33136236. S2CID 226223522.
- ^ "FDA approves dabrafenib–trametinib for BRAF-positive cancers - NCI". 21 July 2022.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |